1
|
Al-Zubaidi HK, Hughes SF. The Use of CD200 in the Differential Diagnosis of B-Cell Lymphoproliferative Disorders. Br J Biomed Sci 2023; 80:11573. [PMID: 37822353 PMCID: PMC10563807 DOI: 10.3389/bjbs.2023.11573] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2023] [Accepted: 09/15/2023] [Indexed: 10/13/2023]
Abstract
Background: B-Cell Lymphoproliferative Disorders (B-LPDs) are a group of heterogenous disorders characterised by the accumulation of B-cells in peripheral blood, bone marrow, lymph nodes and spleen. They have a variable disease course and outcome and many share similar features making differential diagnosis challenging. Therefore, accurate diagnosis is fundamental in particular for determining treatment options. Immunophenotyping by flow cytometry plays a crucial role in the diagnosis of B-LPDs. However, overlapping immunophenotyping patterns exist and the use of novel monoclonal antibodies has become increasingly important in immunophenotyping analysis. More recently differential expression of CD200 has been reported in various B-LPDs and that CD200 may improve the differentiation between chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL). In this study CD200 expression is evaluated in different B-LPDs. Methods: A total of 100 samples were collected and analysed by immunophenotyping flow cytometry over a period of 1 year (2017-2018), by a panel of monoclonal antibodies including CD200. The percentage of CD200 and its expression intensity was evaluated and compared between different groups of B-LPDs. Results: All of the 50 cases of CLL expressed CD200 with moderate to bright intensity, 6 MCL cases lacked the expression of CD200. Furthermore, all 5 cases of hairy cell leukaemia (HCL) expressed CD200. Out of all B-LPDs evaluated, CD200 expression in HCL cases was noted to be the brightest. The other 39 cases were not found to be B-LPDs. Conclusion: CD200 has an important role in differentiating CLL from MCL, HCL has a consistent bright expression of CD200. By adding CD200 to the combinations of markers in routine testing panel, Immunophenotyping by flow cytometry can be an effective tool in the diagnosis of B-LPDs especially in cases with atypical immunophenotyping pattern. Our result support that CD200 can be added to routine testing panel as it is useful in differentiating them.
Collapse
MESH Headings
- Humans
- Antibodies, Monoclonal/metabolism
- B-Lymphocytes/metabolism
- B-Lymphocytes/pathology
- Diagnosis, Differential
- Flow Cytometry
- Immunophenotyping
- Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis
- Leukemia, Lymphocytic, Chronic, B-Cell/metabolism
- Lymphoma, Mantle-Cell/diagnosis
- Lymphoma, Mantle-Cell/pathology
Collapse
Affiliation(s)
- Hanaan Kareem Al-Zubaidi
- Pathology Department, Ysbyty Gwynedd, Betsi Cadwaladr University Health Board, Bangor, United Kingdom
| | - Stephen Fôn Hughes
- Maelor Academic Unite (MAU), Betsi Cadwaladr University Health Board, Wrexham, United Kingdom
| |
Collapse
|
2
|
Jalal SD. The contribution of CD200 to the diagnostic accuracy of Matutes score in the diagnosis of chronic lymphocytic leukemia in limited resources laboratories. PLoS One 2021; 16:e0247491. [PMID: 33606850 PMCID: PMC7895405 DOI: 10.1371/journal.pone.0247491] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2020] [Accepted: 02/04/2021] [Indexed: 12/15/2022] Open
Abstract
Flow cytometry immunophenotyping has an essential role in distinguishing chronic lymphocytic leukemia from other B-chronic lymphoproliferative disorders. Recently, CD200 is considered as a relatively consistent marker in chronic lymphocytic leukemia. We retrospectively assessed CD200 expression in 252 patients with B chronic lymphoproliferative disorders with four-color flow cytometry. CD200 expression estimation included the proportion of positive cells (≥30%) and the mean fluorescence intensity ratio. Additionally, we have incorporated CD200 into Matutes score, also replaced FMC7 and CD79b in an attempt to improve the score discriminative power. Of 252 patients enrolled, 199(79%) patients were classified as chronic lymphocytic leukemia and 53 (21%) as other B-chronic lymphoproliferative disorders. All chronic lymphocytic leukemia cases and 20 of 53 (37.7%) of other B-chronic lymphoproliferative disorders demonstrated high CD200 expression (≥30%). Further, CD200 (≥30%) revealed a higher accuracy in comparison to other markers in Matutes score (range: 51%–92.5%). Also, CD200 addition to the Matutes score has correctly recognized all 199 chronic lymphocytic leukemia cases including 10 atypical chronic lymphocytic leukemia cases. As for non-CLL cases, 20 of 53 attained a higher score, yet keeping the original diagnosis. Moreover, CD200 enhanced the diagnostic accuracy of Matutes score to 100%, and when included in a simplified 4-markers score, showed an accuracy of 99.8% compared to 99.4% of Matutes score. In conclusion, CD200 is an accurate diagnostic marker for chronic lymphocytic leukemia, and can refine the modified Matutes score accuracy when added with other markers.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Antigens, CD/blood
- Biomarkers, Tumor/blood
- Diagnosis, Differential
- Female
- Flow Cytometry
- Humans
- Immunophenotyping
- Leukemia, Lymphocytic, Chronic, B-Cell/blood
- Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis
- Male
- Middle Aged
- Retrospective Studies
Collapse
Affiliation(s)
- Sana Dlawar Jalal
- Department of Pathology, College of Medicine, University of Sulaimani, Sulaimani, Iraq
- * E-mail:
| |
Collapse
|
3
|
D'Arena G, De Feo V, Pietrantuono G, Seneca E, Mansueto G, Villani O, La Rocca F, D'Auria F, Statuto T, Valvano L, Arruga F, Deaglio S, Efremov DG, Sgambato A, Laurenti L. CD200 and Chronic Lymphocytic Leukemia: Biological and Clinical Relevance. Front Oncol 2020; 10:584427. [PMID: 33324560 PMCID: PMC7727446 DOI: 10.3389/fonc.2020.584427] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2020] [Accepted: 10/27/2020] [Indexed: 12/28/2022] Open
Abstract
CD200, a transmembrane type Ia glycoprotein belonging to the immunoglobulin protein superfamily, is broadly expressed on a wide variety of cell types, such as B lymphocytes, a subset of T lymphocytes, dendritic cells, endothelial and neuronal cells. It delivers immunosuppressive signals through its receptor CD200R, which is expressed on monocytes/myeloid cells and T lymphocytes. Moreover, interaction of CD200 with CD200R has also been reported to play a role in the regulation of tumor immunity. Overexpression of CD200 has been reported in chronic lymphocytic leukemia (CLL) and hairy cell leukemia but not in mantle cell lymphoma, thus helping to better discriminate between these different B cell malignancies with different prognosis. In this review, we focus on the role of CD200 expression in the differential diagnosis of mature B-cell neoplasms and on the prognostic significance of CD200 expression in CLL, where conflicting results have been published so far. Of interest, increasing evidences indicate that anti-CD200 treatment might be therapeutically beneficial for treating CD200-expressing malignancies, such as CLL.
Collapse
Affiliation(s)
- Giovanni D'Arena
- Hematology, "S. Luca" Hospital, ASL Salerno, Vallo della Lucania, Italy
| | - Vincenzo De Feo
- Department of Pharmaceutical and Biomedical Sciences, University of Salerno, Salerno, Italy
| | - Giuseppe Pietrantuono
- Hematology and Stem Cell Transplantation Unit, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy
| | - Elisa Seneca
- Hematology and Stem Cell Transplantation Unit, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy
| | - Giovanna Mansueto
- Hematology and Stem Cell Transplantation Unit, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy
| | - Oreste Villani
- Hematology and Stem Cell Transplantation Unit, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy
| | - Francesco La Rocca
- Laboratory of Preclinical and Translational Diagnostics, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy
| | - Fiorella D'Auria
- Laboratory of Clinical Research and Advanced Diagnostics, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy
| | - Teodora Statuto
- Laboratory of Clinical Research and Advanced Diagnostics, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy
| | - Luciana Valvano
- Laboratory of Clinical Research and Advanced Diagnostics, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy
| | - Francesca Arruga
- Cancer Immunogenetics Unit, Department of Medical Sciences, Molecular Biotechnology Center, University of Turin, Turin, Italy
| | - Silvia Deaglio
- Cancer Immunogenetics Unit, Department of Medical Sciences, Molecular Biotechnology Center, University of Turin, Turin, Italy
| | - Dimitar G Efremov
- Molecular Hematology, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy
| | - Alessandro Sgambato
- Scientific Direction, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy
| | - Luca Laurenti
- Hematology Institute, IRCCS Fondazione Policlinico Universitario A. Gemelli, Rome, Italy
| |
Collapse
|
4
|
Sorigue M, Magnano L, Miljkovic MD, Nieto‐Moragas J, Santos‐Gomez M, Villamor N, Junca J, Morales‐Indiano C. Positive predictive value of CD200 positivity in the differential diagnosis of chronic lymphocytic leukemia. CYTOMETRY PART B-CLINICAL CYTOMETRY 2019; 98:441-448. [DOI: 10.1002/cyto.b.21849] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/16/2019] [Revised: 09/25/2019] [Accepted: 10/02/2019] [Indexed: 12/17/2022]
Affiliation(s)
- Marc Sorigue
- Hematology Laboratory, ICO‐Hospital Germans Trias i Pujol. IJC Universitat Autònoma de Barcelona Badalona Spain
| | - Laura Magnano
- Hematopathology Unit, Department of Pathology Hospital Clinic de Barcelona Barcelona Spain
| | - Milos D. Miljkovic
- Lymphoid Malignancies Branch National Cancer Institute Bethesda Maryland
| | | | - Mireia Santos‐Gomez
- Hematology Laboratory, ICO‐Hospital Germans Trias i Pujol. IJC Universitat Autònoma de Barcelona Badalona Spain
| | - Neus Villamor
- Hematopathology Unit, Department of Pathology Hospital Clinic de Barcelona Barcelona Spain
| | - Jordi Junca
- Hematology Laboratory, ICO‐Hospital Germans Trias i Pujol. IJC Universitat Autònoma de Barcelona Badalona Spain
| | - Cristian Morales‐Indiano
- Clinical Laboratory ICS‐Metropolitana Nord, Core‐hematology Department Hospital Germans Trias i Pujol Badalona Spain
| |
Collapse
|
5
|
Salem DA, Scott D, McCoy CS, Liewehr DJ, Venzon DJ, Arons E, Kreitman RJ, Stetler-Stevenson M, Yuan CM. Differential Expression of CD43, CD81, and CD200 in Classic Versus Variant Hairy Cell Leukemia. CYTOMETRY PART B-CLINICAL CYTOMETRY 2019; 96:275-282. [PMID: 31077558 DOI: 10.1002/cyto.b.21785] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/15/2018] [Revised: 04/05/2019] [Accepted: 04/19/2019] [Indexed: 12/14/2022]
Abstract
BACKGROUND Hairy cell leukemia (HCL) and hairy cell leukemia variant (HCLv) are rare diseases with overlapping clinicopathological features. Features distinguishing HCL from HCLv include expression of CD25, CD123, CD200, annexin-A1, and the presence of BRAF V600E mutation. HCLv typically lacks these markers, but they may occur in a subgroup of HCL patients with an aggressive clinical course. We examined CD43, CD81, CD79b, and CD200 expression in HCL and HCLv. METHODS Multiparametric flow cytometry (FCM) was performed on blood from 59 HCL and 15 HCLv patients for protocol entry. Mean fluorescent intensity (MFI) of CD43, CD79b, CD81, and CD200 was determined (for CD200, n = 17 and 7, respectively). RESULTS Median MFI of HCL vs HCLv was 545 vs 272 for CD43, 602 vs 2,450 for CD81, 4,962 vs 1,969 for CD79b, and 11,652 vs 1,405 for CD200, respectively. Analysis of the median differences, HCL minus HCLv (and their 95% confidence intervals and P-values) indicated that CD43 MFI (estimated median difference (95% CI): 212 [72-413; P = 0.0027) and CD200 MFI (9,883 [3,514-13,434]; P < 0.0001) were higher in HCL than in HCLv, while CD81 MFI (-1,858 [-2,604 to -1,365]; P < 0.0001) was lower in HCL than in HCLv. CD79b MFI HCL median was more than double that of HCLv, but the observed difference (1,571 [-739 to 4,417]) was consistent with the null hypothesis of no difference (P = 0.13). CONCLUSIONS CD200, CD43, and CD81 are likely differentially expressed between HCL and HCLv, reflecting their differing disease biology. Inclusion of these markers in FCM is potentially informative. © 2019 International Clinical Cytometry Society.
Collapse
Affiliation(s)
- Dalia A Salem
- Laboratory of Pathology, CCR, NCI, NIH, Bethesda, Maryland.,Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt
| | - Drake Scott
- Laboratory of Pathology, CCR, NCI, NIH, Bethesda, Maryland
| | | | - David J Liewehr
- Biostatistics and Data Management Section, CCR, NCI, NIH, Bethesda, Maryland
| | - David J Venzon
- Biostatistics and Data Management Section, CCR, NCI, NIH, Bethesda, Maryland
| | - Evgeny Arons
- Laboratory of Molecular Biology, Clinical Immunotherapy Section, CCR, NCI, NIH, Bethesda, Maryland
| | - Robert J Kreitman
- Laboratory of Molecular Biology, Clinical Immunotherapy Section, CCR, NCI, NIH, Bethesda, Maryland
| | | | | |
Collapse
|
6
|
Mora A, Bosch R, Cuellar C, Vicente EP, Blanco L, Martino R, Ubeda JM, Sierra J, Moreno C, Nomdedeu J. CD200 is a useful marker in the diagnosis of chronic lymphocytic leukemia. CYTOMETRY PART B-CLINICAL CYTOMETRY 2018; 96:143-148. [DOI: 10.1002/cyto.b.21722] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/21/2018] [Revised: 05/25/2018] [Accepted: 06/26/2018] [Indexed: 12/22/2022]
Affiliation(s)
- Alba Mora
- Laboratory of Oncology/Hematology and TransplantationInstitute of Biomedical Research Barcelona Spain
- Department of Hematology, Hospital de la Santa Creu i Sant PauAutonomous University of Barcelona Spain
- Department of MedicineAutonomous University of Barcelona Barcelona Spain
- Biomedical Research Institute (IIB‐Sant Pau) and José Carreras Leukemia Research Institute
| | - Rosa Bosch
- Laboratory of Oncology/Hematology and TransplantationInstitute of Biomedical Research Barcelona Spain
- Department of Hematology, Hospital de la Santa Creu i Sant PauAutonomous University of Barcelona Spain
- Biomedical Research Institute (IIB‐Sant Pau) and José Carreras Leukemia Research Institute
| | - Carolina Cuellar
- Laboratory of Oncology/Hematology and TransplantationInstitute of Biomedical Research Barcelona Spain
- Department of Hematology, Hospital de la Santa Creu i Sant PauAutonomous University of Barcelona Spain
- Biomedical Research Institute (IIB‐Sant Pau) and José Carreras Leukemia Research Institute
| | - Eva Puy Vicente
- Laboratory of Oncology/Hematology and TransplantationInstitute of Biomedical Research Barcelona Spain
- Department of Hematology, Hospital de la Santa Creu i Sant PauAutonomous University of Barcelona Spain
| | - Laura Blanco
- Laboratory of HematologyHospital de la Santa Creu i Sant Pau Barcelona Spain
| | - Rodrigo Martino
- Department of Hematology, Hospital de la Santa Creu i Sant PauAutonomous University of Barcelona Spain
| | - José M. Ubeda
- Laboratory of HematologyHospital de la Santa Creu i Sant Pau Barcelona Spain
| | - Jorge Sierra
- Laboratory of Oncology/Hematology and TransplantationInstitute of Biomedical Research Barcelona Spain
- Department of Hematology, Hospital de la Santa Creu i Sant PauAutonomous University of Barcelona Spain
- Biomedical Research Institute (IIB‐Sant Pau) and José Carreras Leukemia Research Institute
| | - Carol Moreno
- Laboratory of Oncology/Hematology and TransplantationInstitute of Biomedical Research Barcelona Spain
- Department of Hematology, Hospital de la Santa Creu i Sant PauAutonomous University of Barcelona Spain
- Department of MedicineAutonomous University of Barcelona Barcelona Spain
- Biomedical Research Institute (IIB‐Sant Pau) and José Carreras Leukemia Research Institute
| | - Josep Nomdedeu
- Laboratory of HematologyHospital de la Santa Creu i Sant Pau Barcelona Spain
| |
Collapse
|
7
|
Tomuleasa C, Selicean C, Cismas S, Jurj A, Marian M, Dima D, Pasca S, Petrushev B, Moisoiu V, Micu WT, Vischer A, Arifeen K, Selicean S, Zdrenghea M, Bumbea H, Tanase A, Grewal R, Pop L, Aanei C, Berindan-Neagoe I. Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently available laboratory approaches. Crit Rev Clin Lab Sci 2018; 55:329-345. [PMID: 29801428 DOI: 10.1080/10408363.2018.1463508] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Chronic lymphocytic leukemia (CLL) is a malignancy defined by the accumulation of mature lymphocytes in the lymphoid tissues, bone marrow, and blood. Therapy for CLL is guided according to the Rai and Binet staging systems. Nevertheless, state-of-the-art protocols in disease monitoring, diagnostics, and prognostics for CLL are based on the assessment of minimal residual disease (MRD). MRD is internationally considered to be the level of disease that can be detected by sensitive techniques and represents incomplete treatment and a probability of disease relapse. MRD detection has been continuously improved by the quick development of both flow cytometry and molecular biology technology, as well as by next-generation sequencing. Considering that MRD detection is moving more and more from research to clinical practice, where it can be an independent prognostic marker, in this paper, we present the methodologies by which MRD is evaluated, from translational research to clinical practice.
Collapse
Affiliation(s)
- Ciprian Tomuleasa
- a Department of Hematology , Ion Chiricuta Clinical Cancer Center , Cluj Napoca , Romania.,b Research Center for Functional Genomics and Translational Medicine/Hematology , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania
| | - Cristina Selicean
- a Department of Hematology , Ion Chiricuta Clinical Cancer Center , Cluj Napoca , Romania
| | - Sonia Cismas
- c Department of Genetics , Victor Babes University of Medicine and Pharmacy , Timisoara , Romania.,d Department of Hematology , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania
| | - Anca Jurj
- e Research Center for Functional Genomics and Translational Medicine , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania
| | - Mirela Marian
- a Department of Hematology , Ion Chiricuta Clinical Cancer Center , Cluj Napoca , Romania
| | - Delia Dima
- a Department of Hematology , Ion Chiricuta Clinical Cancer Center , Cluj Napoca , Romania
| | - Sergiu Pasca
- e Research Center for Functional Genomics and Translational Medicine , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania
| | - Bobe Petrushev
- e Research Center for Functional Genomics and Translational Medicine , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania
| | - Vlad Moisoiu
- e Research Center for Functional Genomics and Translational Medicine , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania
| | - Wilhelm-Thomas Micu
- e Research Center for Functional Genomics and Translational Medicine , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania
| | - Anna Vischer
- d Department of Hematology , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania
| | - Kanza Arifeen
- d Department of Hematology , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania
| | - Sonia Selicean
- d Department of Hematology , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania
| | - Mihnea Zdrenghea
- a Department of Hematology , Ion Chiricuta Clinical Cancer Center , Cluj Napoca , Romania.,d Department of Hematology , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania
| | - Horia Bumbea
- f Department of Hematology , Carol Davila University of Medicine and Pharmacy , Bucharest , Romania.,g Department of Hematology , University Clinical Hospital , Bucharest , Romania
| | - Alina Tanase
- h Department of Stem Cell Transplantation , Fundeni Clinical Institute , Bucharest , Romania
| | - Ravnit Grewal
- i South African Medical Research Council Bioinformatics Unit , The South African National Bioinformatics Institute (SANBI), University of the Western Cape , Bellville , South Africa
| | - Laura Pop
- e Research Center for Functional Genomics and Translational Medicine , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania
| | - Carmen Aanei
- j Hematology Laboratory, Pole de Biologie-Pathologie , University Hospital of St. Etienne , St. Etienne , France
| | - Ioana Berindan-Neagoe
- e Research Center for Functional Genomics and Translational Medicine , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania
| |
Collapse
|
8
|
Favre R, Manzoni D, Traverse-Glehen A, Verney A, Jallades L, Callet-Bauchu E, Sujobert P, Salles G, Baseggio L. Usefulness of CD200 in the differential diagnosis of SDRPL, SMZL, and HCL. Int J Lab Hematol 2018; 40:e59-e62. [DOI: 10.1111/ijlh.12824] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2017] [Accepted: 03/08/2018] [Indexed: 11/28/2022]
Affiliation(s)
- R. Favre
- Department of Hematologic Laboratory; Hospices Civils De Lyon/GHS; Lyon France
| | - D. Manzoni
- Department of Hematologic Laboratory; Hospices Civils De Lyon/GHS; Lyon France
| | - A. Traverse-Glehen
- Department of Anatomic Pathology; Hospices Civils De Lyon/GHS; Lyon France
- Cancer Research Center of Lyon; INSERM 1052-CNRS UMR5286 « Clinical and Experimental Models of Lymphomagenesis »; Lyon France
| | - A. Verney
- Cancer Research Center of Lyon; INSERM 1052-CNRS UMR5286 « Clinical and Experimental Models of Lymphomagenesis »; Lyon France
| | - L. Jallades
- Department of Hematologic Laboratory; Hospices Civils De Lyon/GHS; Lyon France
- Cancer Research Center of Lyon; INSERM 1052-CNRS UMR5286 « Clinical and Experimental Models of Lymphomagenesis »; Lyon France
| | - E. Callet-Bauchu
- Department of Hematologic Laboratory; Hospices Civils De Lyon/GHS; Lyon France
- Cancer Research Center of Lyon; INSERM 1052-CNRS UMR5286 « Clinical and Experimental Models of Lymphomagenesis »; Lyon France
| | - P. Sujobert
- Department of Hematologic Laboratory; Hospices Civils De Lyon/GHS; Lyon France
- Cancer Research Center of Lyon; INSERM 1052-CNRS UMR5286 « Clinical and Experimental Models of Lymphomagenesis »; Lyon France
| | - G. Salles
- Cancer Research Center of Lyon; INSERM 1052-CNRS UMR5286 « Clinical and Experimental Models of Lymphomagenesis »; Lyon France
- Department of Clinic Hematology; Hospices Civils De Lyon/GHS; Lyon France
| | - L. Baseggio
- Department of Hematologic Laboratory; Hospices Civils De Lyon/GHS; Lyon France
- Cancer Research Center of Lyon; INSERM 1052-CNRS UMR5286 « Clinical and Experimental Models of Lymphomagenesis »; Lyon France
| |
Collapse
|
9
|
Debord C, Robillard N, Theisen O, Gastinne T, Godmer P, Graveleau J, Le Gouill S, Luycx O, Tiab M, Loirat M, Lestang E, Wuillème S, Godon C, Eveillard M, Béné MC. CD200 expression in flow cytometry helps to distinguish mantle cell lymphoma from other CD5-positive B-cell neoplasms. Hematol Oncol 2018; 36:607-609. [PMID: 29656538 DOI: 10.1002/hon.2511] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2018] [Revised: 02/13/2018] [Accepted: 03/13/2018] [Indexed: 11/08/2022]
Affiliation(s)
- Camille Debord
- Hematology Biology, Nantes University Hospital, Nantes, France
| | - Nelly Robillard
- Hematology Biology, Nantes University Hospital, Nantes, France
| | - Olivier Theisen
- Hematology Biology, Nantes University Hospital, Nantes, France
| | - Thomas Gastinne
- Department of Hematology, Nantes University Hospital, Nantes, France
| | - Pascal Godmer
- Department of Hematology, Bretagne Atlantique Hospital, Vannes, France
| | - Julie Graveleau
- Department of Internal Medicine, St Nazaire Hospital, Saint-Nazaire, France
| | - Steven Le Gouill
- Department of Hematology, Nantes University Hospital, Nantes, France
| | - Odile Luycx
- Department of Hematology, Bretagne Sud Hospital, Lorient, France
| | - Mourad Tiab
- Department of Hematology, Vendée Hospital, La Roche sur Yon, France
| | - Marion Loirat
- Department of Internal Medicine, St Nazaire Hospital, Saint-Nazaire, France
| | - Elsa Lestang
- Department of Internal Medicine, St Nazaire Hospital, Saint-Nazaire, France
| | - Soraya Wuillème
- Hematology Biology, Nantes University Hospital, Nantes, France
| | - Catherine Godon
- Hematology Biology, Nantes University Hospital, Nantes, France
| | | | | |
Collapse
|
10
|
D'Arena G, Vitale C, Rossi G, Coscia M, Omedè P, D'Auria F, Statuto T, Valvano L, Ciolli S, Gilestro M, Molica S, Bellesi S, Topini G, Panichi V, Autore F, Innocenti I, Musto P, Deaglio S, Laurenti L, Del Vecchio L. CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia. Hematol Oncol 2018; 36:543-546. [PMID: 29602219 DOI: 10.1002/hon.2510] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2017] [Revised: 01/26/2018] [Accepted: 03/05/2018] [Indexed: 12/27/2022]
Abstract
CD200, a transmembrane type Ia glycoprotein belonging to the immunoglobulin superfamily, has been shown to have a differential expression in B-cell neoplasms. Here, we retrospectively assessed the diagnostic relevance of CD200 on 427 patients with B-cell chronic neoplasms in leukemic phase (median age, 69 y; range, 35-97 y). The final diagnosis based on the investigator's assessment was chronic lymphocytic leukaemia (CLL) in 75% of cases and non-CLL in 25% of cases. Sensitivity and specificity for the diagnosis of CLL (vs non-CLL) were calculated for the following markers: CD200, CD5, CD22, CD23, CD79b, FMC7, and SmIg. CD23 was the only marker without a statistically significant difference between the investigator assessment and the flowcytometric analysis. The other markers were unable-when individually evaluated-to discriminate between CLL and non-CLL, requiring the integration into a scoring system. The modified score no. 1 (addition of CD200) showed superimposable sensitivity and specificity compared with the Matutes score. The substitution of CD79b (modified score no. 2), surface membrane immunoglobulins (SmIg) (modified score no. 3), and CD79b and FMC7 (modified score no. 4) with CD200 showed that only the modified score no. 4 had both higher sensitivity and higher specificity compared with standard Matutes score. In conclusion, this work defines a simplified score, compared with the classical Matutes score, for the differential diagnosis of chronic B-cell leukaemia-which only requires 4 markers instead of 5 (CD5, CD23, CD200, and SmIg).
Collapse
Affiliation(s)
- Giovanni D'Arena
- Hematology and Stem Cell Transplantation Unit, IRCCS Referral Cancer Center of Basilicata, Rionero in Vulture, Italy
| | - Candida Vitale
- Division of Hematology, University of Torino, Torino, Italy
| | - Giovanni Rossi
- Hematology Unit and Stem Cell Transplantation, IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Italy
| | - Marta Coscia
- Division of Hematology, University of Torino, Torino, Italy
| | - Paola Omedè
- Division of Hematology, University of Torino, Torino, Italy
| | - Fiorella D'Auria
- Laboratory of Clinical Research and Advances Diagnostics, IRCCS Referral Cancer Center of Basilicata, Rionero in Vulture, Italy
| | - Teodora Statuto
- Laboratory of Clinical Research and Advances Diagnostics, IRCCS Referral Cancer Center of Basilicata, Rionero in Vulture, Italy
| | - Luciana Valvano
- Laboratory of Clinical Research and Advances Diagnostics, IRCCS Referral Cancer Center of Basilicata, Rionero in Vulture, Italy
| | | | | | - Stefano Molica
- Hematology Unit, "Pugliese e Ciaccio" Hospital, Catanzaro, Italy
| | - Silvia Bellesi
- Hematology Unit, Catholic University of "Sacred Hearth", Rome, Italy
| | - Giuseppe Topini
- Department of Onco-Hematology, Belcolle Hospital, Viterbo, Italy
| | | | - Francesco Autore
- Hematology Unit, Catholic University of "Sacred Hearth", Rome, Italy
| | - Idanna Innocenti
- Hematology Unit, Catholic University of "Sacred Hearth", Rome, Italy
| | - Pellegrino Musto
- Scientific Direction, IRCCS Cancer Referral Center of Basilicata, Rionero in Vulture, Italy
| | - Silvia Deaglio
- Italian Institute for Genomic Medicine (IIGM), University of Torino, Turin, Italy
| | - Luca Laurenti
- Hematology Unit, Catholic University of "Sacred Hearth", Rome, Italy
| | - Luigi Del Vecchio
- CEINGE-Biotecnologie Avanzate s.c.a.r.l., "Federico II" University, Naples, Italy
- Department of Molecular Medicine and Medical Biotechnology, "Federico II" University, Naples, Italy
| |
Collapse
|
11
|
Panel proposal for the immunophenotypic diagnosis of hematological malignancies. A collaborative consensus from the groupe d'Etude Immunologique des Leucémies (GEIL). CYTOMETRY PART B-CLINICAL CYTOMETRY 2017; 94:542-547. [DOI: 10.1002/cyto.b.21602] [Citation(s) in RCA: 54] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/27/2017] [Revised: 11/11/2017] [Accepted: 11/20/2017] [Indexed: 11/09/2022]
|